ArticleCureus2025
Prevalence and Prognostic Impact of Diabetes Mellitus in Hospitalized COVID-19 Patients: A Monocentric Study From India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background COVID-19 has been a fatal pandemic in modern history, with diabetes mellitus (DM) as a common comorbidity. However, data on the effect of DM on Indian COVID-19 patients are still scarce. We aimed to evaluate the prevalence and prognostic impact of DM in COVID-19 patients hospitalized at Index Medical College Hospital and Research Center (IMCHRC), Indore, Madhya Pradesh. Methods This is a retrospective monocentric observational study including all consecutive adult COVID-19 patients admitted to our center from July 2021 to March 2022. Data including demographics, clinical features, DM history, laboratory investigations, comorbidities, disease severity, intensive care unit (ICU) admission, invasive fungal infections, multi-organ dysfunction, and death were retrieved from the medical records of the patients and analyzed. Results A total of 357 COVID-19 patients (236 males) with a mean age of 52+9.7 years were evaluated. The overall prevalence of DM in the patients was 32% (115/357), comprising of 23% (83/357) cases of pre-existing DM and 9% (32/357) cases of new onset of DM. Vascular comorbidities consisting of hypertension (62% vs 27%; p=0.002), cardiovascular disease (39% vs 21%; p=0.016), and kidney disease (42% vs 27%; p=0.019) were significantly associated with DM. Diabetic versus non-diabetic COVID-19 patients had a higher rate of ICU admission (23% vs 10%; p=0.042), severe disease (43% [49/115] vs 5% [13/242]; p=0.002), acute respiratory distress syndrome (25% vs 7%), secondary infections (30% vs 11%; p=0.033), multi-organ dysfunction (16% vs 9%; p=0.045), and in-hospital mortality (21% [24/115] vs 6% [15/242]; p=0.011). Conclusions Our study shows a high prevalence of DM in COVID-19 patients and an adverse effect of DM on the prognosis of COVID-19 patients including increased disease severity and in-hospital mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.